PE20230163A1 - Compuesto de piridazinil-tiazolcarboxamida - Google Patents
Compuesto de piridazinil-tiazolcarboxamidaInfo
- Publication number
- PE20230163A1 PE20230163A1 PE2022001161A PE2022001161A PE20230163A1 PE 20230163 A1 PE20230163 A1 PE 20230163A1 PE 2022001161 A PE2022001161 A PE 2022001161A PE 2022001161 A PE2022001161 A PE 2022001161A PE 20230163 A1 PE20230163 A1 PE 20230163A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- compound
- pyridazinyl
- antibodies
- cycloalkyl
- Prior art date
Links
- -1 PYRIDAZINYL-THIAZOLCARBOXAMIDE COMPOUND Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- COWCRHWOKQJCGT-KRWDZBQOSA-N N-[2-[(3S)-3-(aminomethyl)piperidin-1-yl]-4-phenoxy-3-(trifluoromethyl)phenyl]-2-pyridazin-4-yl-1,3-thiazole-4-carboxamide Chemical compound C1C[C@H](CN(C1)C2=C(C=CC(=C2C(F)(F)F)OC3=CC=CC=C3)NC(=O)C4=CSC(=N4)C5=CN=NC=C5)CN COWCRHWOKQJCGT-KRWDZBQOSA-N 0.000 abstract 1
- ITXFKBXNWXVSDP-UHFFFAOYSA-N NC(C1=NC(C2=CC=CN=N2)=CS1)=O Chemical compound NC(C1=NC(C2=CC=CN=N2)=CS1)=O ITXFKBXNWXVSDP-UHFFFAOYSA-N 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invencion se refiere a un compuesto derivados de piridazinil-tiazolcarboxamida de formula (I); en donde R1 es un grupo de formula (i), (ii), (iii) (iv) o (v); R2 es alquiloC1-6, cicloalquilo C3 5, halogeno alquilo C1 6, entre otros; R3 es fenilo opcionalmente sustituido con alquilo C1 6, halogeno alquilo C1 6, cicloalquilo C3 5, entre otros; R4 es H o F; L es un enlace, CO, SO2, O o NH; X es CH2, O o N metilo; Y es CH2 u O; m y n son 1 o 2; y Ra, Rb, Rc y Rd son, independientemente, H, metilo, entre otros. Un compuesto seleccionado es N-{2-[(3S)-3-(aminometil)piperidin-1-il]-4-fenoxi-3-(trifluorometil)fenil}-2-(piridazi n-4-il)-1,3-tiazol-4-carboxamida. Tambien refiera a una composicion farmaceutica que los comprende. Dicho compuesto tiene efecto inhibitorio sobre DGK Xi (DGKzeta) siendo utiles para el tratamiento del cancer relacionado con la activacion de celulas inmunitarias o del cancer que ofrece resistencia a un tratamiento con anticuerpos anti-PD-1/anticuerpos anti-PD-L1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019233673 | 2019-12-25 | ||
| PCT/JP2020/048337 WO2021132422A1 (ja) | 2019-12-25 | 2020-12-24 | ピリダジニルチアアゾールカルボキシアミド化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230163A1 true PE20230163A1 (es) | 2023-02-01 |
Family
ID=76574296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001161A PE20230163A1 (es) | 2019-12-25 | 2020-12-24 | Compuesto de piridazinil-tiazolcarboxamida |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US12227517B2 (es) |
| EP (1) | EP4083038B1 (es) |
| JP (1) | JP6948659B1 (es) |
| KR (1) | KR20220119702A (es) |
| CN (3) | CN115590854B (es) |
| AR (1) | AR120896A1 (es) |
| AU (1) | AU2020413997A1 (es) |
| BR (1) | BR112022012637A2 (es) |
| CA (1) | CA3165889A1 (es) |
| CL (1) | CL2022001752A1 (es) |
| CO (1) | CO2022009124A2 (es) |
| CR (1) | CR20220328A (es) |
| DK (1) | DK4083038T3 (es) |
| DO (1) | DOP2022000137A (es) |
| EC (1) | ECSP22057324A (es) |
| ES (1) | ES2995459T3 (es) |
| FI (1) | FI4083038T3 (es) |
| HR (1) | HRP20241588T1 (es) |
| HU (1) | HUE069173T2 (es) |
| IL (1) | IL294136B2 (es) |
| JO (1) | JOP20220163A1 (es) |
| LT (1) | LT4083038T (es) |
| MX (1) | MX2022007993A (es) |
| MY (1) | MY206825A (es) |
| PE (1) | PE20230163A1 (es) |
| PH (1) | PH12022551569A1 (es) |
| PL (1) | PL4083038T3 (es) |
| PT (1) | PT4083038T (es) |
| SA (1) | SA522433129B1 (es) |
| SI (1) | SI4083038T1 (es) |
| TW (3) | TWI881008B (es) |
| UA (1) | UA129628C2 (es) |
| WO (1) | WO2021132422A1 (es) |
| ZA (1) | ZA202207543B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3001984T3 (en) | 2019-12-24 | 2025-03-06 | Carna Biosciences Inc | Diacylglycerol kinase modulating compounds |
| AR120896A1 (es) | 2019-12-25 | 2022-03-30 | Astellas Pharma Inc | COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz |
| JP7663603B2 (ja) | 2020-04-24 | 2025-04-16 | バイエル・アクチエンゲゼルシヤフト | 免疫活性化のためのｄｇｋｚｅｔａ阻害剤としての置換アミノチアゾール類 |
| CR20230415A (es) | 2020-11-30 | 2023-09-08 | Kotobuki Pharmaceutical Co Ltd | Compuesto de heteroarilcarboxamida |
| AU2022297367B2 (en) | 2021-06-23 | 2025-04-10 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7654118B2 (ja) | 2021-06-23 | 2025-03-31 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| CN114621214B (zh) * | 2022-04-25 | 2024-04-26 | 宜春学院 | 一种抗菌席夫碱n-酰化物及其制备方法和应用 |
| TW202428272A (zh) * | 2022-11-18 | 2024-07-16 | 美商英塞特公司 | 作為ｄｇｋ抑制劑之雜芳基氟烯烴 |
| AR131101A1 (es) * | 2023-01-12 | 2025-02-19 | Incyte Corp | Heteroarilfluoroalquenos como inhibidores de dgk |
| WO2024165470A1 (en) | 2023-02-06 | 2024-08-15 | Bayer Aktiengesellschaft | Combinations of dgk (diacylglycerol kinase) inhibitors |
| WO2024199387A1 (zh) * | 2023-03-30 | 2024-10-03 | 微境生物医药科技(上海)有限公司 | 作为DGKζ抑制剂的化合物 |
| CN120826393A (zh) * | 2023-04-06 | 2025-10-21 | 微境生物医药科技(上海)有限公司 | 作为DGKζ抑制剂的噻唑类化合物 |
| WO2025067360A1 (zh) * | 2023-09-27 | 2025-04-03 | 海思科医药集团股份有限公司 | 一种DGKzeta拮抗剂及其在医药上的应用 |
| WO2025082460A1 (zh) * | 2023-10-20 | 2025-04-24 | 上海先祥医药科技有限公司 | 二酰基甘油激酶抑制剂化合物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7381401B2 (en) | 2004-01-08 | 2008-06-03 | The University Of Chicago | T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase |
| WO2006081391A2 (en) | 2005-01-25 | 2006-08-03 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| EP1983980A4 (en) * | 2006-01-25 | 2010-05-05 | Synta Pharmaceuticals Corp | THIAZOL AND THIADIAZOL COMPOUNDS FOR USES IN RELATION TO INFLAMMATION AND IMMUNITY |
| MX2008013400A (es) * | 2006-04-19 | 2008-11-10 | Astellas Pharma Inc | Derivado de azolcarboxamida. |
| EP2078003B1 (en) * | 2006-10-31 | 2017-03-08 | Merck Sharp & Dohme Corp. | Anilinopiperazine derivatives and methods of use thereof |
| CN111372926A (zh) | 2017-09-06 | 2020-07-03 | 普罗佩纶治疗公司 | Wdr5蛋白质-蛋白质结合的抑制剂 |
| HRP20231253T1 (hr) * | 2018-06-27 | 2024-02-02 | Bristol-Myers Squibb Company | Supstituirani spojevi naftiridina korisni kao aktivatori t stanica |
| AR120896A1 (es) * | 2019-12-25 | 2022-03-30 | Astellas Pharma Inc | COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz |
| JP7663603B2 (ja) | 2020-04-24 | 2025-04-16 | バイエル・アクチエンゲゼルシヤフト | 免疫活性化のためのｄｇｋｚｅｔａ阻害剤としての置換アミノチアゾール類 |
| CR20230415A (es) | 2020-11-30 | 2023-09-08 | Kotobuki Pharmaceutical Co Ltd | Compuesto de heteroarilcarboxamida |
-
2020
- 2020-12-23 AR ARP200103641A patent/AR120896A1/es unknown
- 2020-12-24 AU AU2020413997A patent/AU2020413997A1/en active Pending
- 2020-12-24 TW TW109146029A patent/TWI881008B/zh active
- 2020-12-24 PE PE2022001161A patent/PE20230163A1/es unknown
- 2020-12-24 MX MX2022007993A patent/MX2022007993A/es unknown
- 2020-12-24 ES ES20906466T patent/ES2995459T3/es active Active
- 2020-12-24 FI FIEP20906466.6T patent/FI4083038T3/fi active
- 2020-12-24 PH PH1/2022/551569A patent/PH12022551569A1/en unknown
- 2020-12-24 CN CN202211308268.2A patent/CN115590854B/zh active Active
- 2020-12-24 CR CR20220328A patent/CR20220328A/es unknown
- 2020-12-24 TW TW112145679A patent/TW202413375A/zh unknown
- 2020-12-24 HR HRP20241588TT patent/HRP20241588T1/hr unknown
- 2020-12-24 LT LTEPPCT/JP2020/048337T patent/LT4083038T/lt unknown
- 2020-12-24 SI SI202030542T patent/SI4083038T1/sl unknown
- 2020-12-24 JP JP2021531562A patent/JP6948659B1/ja active Active
- 2020-12-24 TW TW112145680A patent/TW202413376A/zh unknown
- 2020-12-24 MY MYPI2022003381A patent/MY206825A/en unknown
- 2020-12-24 IL IL294136A patent/IL294136B2/en unknown
- 2020-12-24 CN CN202080011114.XA patent/CN113365994B/zh active Active
- 2020-12-24 HU HUE20906466A patent/HUE069173T2/hu unknown
- 2020-12-24 CA CA3165889A patent/CA3165889A1/en active Pending
- 2020-12-24 US US17/427,426 patent/US12227517B2/en active Active
- 2020-12-24 DK DK20906466.6T patent/DK4083038T3/da active
- 2020-12-24 PL PL20906466.6T patent/PL4083038T3/pl unknown
- 2020-12-24 KR KR1020227025714A patent/KR20220119702A/ko active Pending
- 2020-12-24 UA UAA202202632A patent/UA129628C2/uk unknown
- 2020-12-24 PT PT209064666T patent/PT4083038T/pt unknown
- 2020-12-24 JO JOP/2022/0163A patent/JOP20220163A1/ar unknown
- 2020-12-24 BR BR112022012637A patent/BR112022012637A2/pt unknown
- 2020-12-24 EP EP20906466.6A patent/EP4083038B1/en active Active
- 2020-12-24 CN CN202211308277.1A patent/CN115626919B/zh active Active
- 2020-12-24 WO PCT/JP2020/048337 patent/WO2021132422A1/ja not_active Ceased
-
2022
- 2022-06-23 SA SA522433129A patent/SA522433129B1/ar unknown
- 2022-06-24 CL CL2022001752A patent/CL2022001752A1/es unknown
- 2022-06-24 DO DO2022000137A patent/DOP2022000137A/es unknown
- 2022-06-30 CO CONC2022/0009124A patent/CO2022009124A2/es unknown
- 2022-07-07 ZA ZA2022/07543A patent/ZA202207543B/en unknown
- 2022-07-21 EC ECSENADI202257324A patent/ECSP22057324A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20230163A1 (es) | Compuesto de piridazinil-tiazolcarboxamida | |
| PE20220141A1 (es) | Inhibidores de la proteina tirosina fosfatasa | |
| PE20171329A1 (es) | Agentes inmunorreguladores | |
| CL2021001111A1 (es) | Tolilo sustituido como fungicidas | |
| PE20210405A1 (es) | Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de enfermedades dependientes de la proteina con dedos de zinc 2 de la familia ikaros (ikzf2) | |
| PE20210340A1 (es) | Compuestos que contienen pirazolopirimidinona y sus usos | |
| PE20210414A1 (es) | Compuestos inhibidores de rip1 y metodos para preparar y usar los mismos | |
| AR064921A1 (es) | Pirazol-amidas sustituidas antagonistas de receptores alfa 7 nicotinicos de acetilcolina,composiciones farmaceuticas que las contienen y usos para el tratamiento de enfermedades neurologicas,psiquiatricas e inflamatorias. | |
| PE20191020A1 (es) | Compuestos quimicos | |
| UY38368A (es) | Compuestos de isoxazolina para controlar plagas de invertebrados | |
| PE20211054A1 (es) | Compuestos de indolinona para uso como inhibidores de map4k1 | |
| AR082590A1 (es) | Inhibidores de la tirosina-quinasa de bruton | |
| PE20231986A1 (es) | Compuesto de heteroarilcarboxamida | |
| PE20230177A1 (es) | COMPUESTOS HETEROCICLICOS DE ARILMETILENO COMO BLOQUEADORES DEL CANAL SHAKER DE POTASIO Kv1.3 | |
| EA202192146A1 (ru) | Антитела к клаудину 6 и их применение | |
| AR069513A1 (es) | Derivados de amidas del acido 6,7-dihidro -5h-imidazo¿1,2-alfa]imidazol-3-carboxilico, y composiciones farmaceuticas que los contienen | |
| AR053774A1 (es) | Derivados de sulfonilbencimidazol. composiciones farmaceuticas. | |
| AR093758A1 (es) | Inhibidores de aril lactama quinasa | |
| MX2020014087A (es) | Moléculas inmunomoduladoras pequeñas novedosas. | |
| CL2020002588A1 (es) | Compuestos derivados de indol, composiciones que los contienen, útiles en el tratamiento de infestación por helmintos, preferentemente trematodos, en mamíferos. (divisional de solicitud n° 03258-2016) | |
| AR065583A1 (es) | Compuestos macrociclicos y composicion farmaceutica | |
| UY38941A (es) | Nuevas sulfiliminas o sulfoximinas que contienen compuestos heterocíclicos fungicidas | |
| PE20190150A1 (es) | 6-AMINOPIRIDIN-3-IL TIAZOLES COMO MODULADORES DE RORyT | |
| PE20200333A1 (es) | Compuestos y metodos para tratar infecciones bacterianas | |
| ECSP21015020A (es) | Pirazoles fungicidas sustituidos con nitroanilino |